Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts

Osteoarthritis and Cartilage

Volumn 17, Issue 2, 2009, Pages 252-262

  De Mattei, M ^a   Varani, K ^a   Masieri, F F ^a   Pellati, A ^a   Ongaro, A ^a   Fini, M ^b   Cadossi, R ^c   Vincenzi, F ^a   Borea, P A ^a   Caruso, A ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c IGEA Biophysics Laboratory   (Italy)

Author keywords

Adenosine receptors; Electromagnetic field; PGE2; Synovial fibroblasts

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR STIMULATING AGENT; CYCLOHEXYLADENOSINE; CYCLOOXYGENASE 2; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DISEASE CONTROL; DRUG MECHANISM; DRUG RECEPTOR BINDING; ELECTROMAGNETIC FIELD; ENZYME MODIFICATION; FIBROBLAST; IMMUNOASSAY; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIOCYTE;

ADENOSINE; ANIMALS; BINDING, COMPETITIVE; CATTLE; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMAGNETIC FIELDS; FIBROBLASTS; FORSKOLIN; LIPOPOLYSACCHARIDES; RECEPTORS, PURINERGIC P1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 59249094368     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2008.06.002     Document Type: Article

References (63)

1. Pelletier J.P., and Martel-Pelletier J. DMOAD developments: present and future. Bull NYU Hosp Jt Dis 65 3 (2007) 242-248
2. Goldring M.B., and Goldring S.R. Osteoarthritis. J Cell Physiol 213 3 (2007) 626-634
3. Müller-Ladner U., Pap T., Gay R.E., Neidhart M., and Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 1 (2005) 102-110
4. Moulton P.J. Inflammatory joint disease: the role of cytokines, cyclooxygenases and reactive oxygen species. Br J Biomed Sci 53 (1996) 317-324
5. Christodoulou C., and Choy E.H. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med 6 (2006) 13-19
6. Abeles A.M., and Pillinger M.H. The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases. Bull NYU Hosp Jt Dis 64 (2006) 20-24
7. Asano K., Sakai M., Matsuda T., Tanaka H., Fujii K., and Hisamitsu T. Suppression of matrix metalloproteinase production from synovial fibroblasts by meloxicam in-vitro. J Pharm Pharmacol 58 (2006) 359-366
8. Westra J., Limburg P.C., De Boer P., and Van Rijswijk M.H. Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis 63 (2004) 1453-1459
9. Davidson R.K., Waters J.G., Kevorkian L., Darrah C., Cooper A., Donell S.T., et al. Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther 8 (2006) R124
10. Park J.Y., Pillinger M.H., and Abramson S.B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 119 (2006) 229-240
11. Burger D., Begué-Pastor N., Benavent S., Gruaz L., Kaufmann M.T., Chicheportiche R., et al. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 42 (2003) 89-96
12. Fahmi H., He Y., Zhang M., Martel-Pelletier J., Pelletier J.P., and Di Battista J.A. Nimesulide reduces interleukin-1beta-induced cyclooxygenase-2 gene expression in human synovial fibroblasts. Osteoarthritis Cartilage 9 (2001) 332-340
13. Goetzl E.J., An S., and Smith W.L. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J 9 (1995) 1051-1058
14. Berenbaum F. Proinflammatory cytokines, prostaglandins, and the chondrocyte: mechanisms of intracellular activation. Joint Bone Spine 67 (2000) 561-564
15. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
16. Crofford L.J. COX-2 in synovial tissues. Osteoarthritis Cartilage 7 (1999) 406-408
17. Hill C.L., Gale D.G., Chaisson C.E., Skinner K., Kazis L., Gale M.E., et al. Knee effusions, popliteal cysts, and synovial thickening: association with knee pain in osteoarthritis. J Rheumatol 28 (2001) 1330-1337
18. Cha H.S., Ahn K.S., Jeon C.H., Kim J., and Koh E.M. Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes. Rheumatol Int 24 (2004) 207-211
19. Agro A., Langdon C., Smith F., and Richards C.D. Prostaglandin E2 enhances interleukin 8 (IL-8) and IL-6 but inhibits GMCSF production by IL-1 stimulated human synovial fibroblasts in vitro. J Rheumatol 23 (1996) 862-868
20. Schnitzer T.J. Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors. Clin Ther 23 (2001) 313-326
21. Hochberg M.C., Altman R.D., Brandt K.D., Clark B.M., Dieppe P.A., Griffin M.R., et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. [American College of Rheumatology]. Arthritis Rheum 38 (1995) 1535-1540
22. Hochberg M.C., Altman R.D., Brandt K.D., Clark B.M., Dieppe P.A., Griffin M.R., et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. [American College of Rheumatology]. Arthritis Rheum 38 (1995) 1541-1546
23. 2 receptors and activity is potentiated by an adenosine deaminase inhibitor and a phosphodiesterase inhibitor. Osteoarthritis Cartilage 10 (2002) 34-43
24. Tesch A.M., MacDonald M.H., Kollas-Baker C., and Benton H.P. Endogenously produced adenosine regulates articular cartilage matrix homeostasis: enzymatic depletion of adenosine stimulates matrix degradation. Osteoarthritis Cartilage 12 (2004) 349-359
25. Cohen S.B., Gill S.S., Baer G.S., Leo B.M., Scheld W.M., and Diduch D.R. Reducing joint destruction due to septic arthrosis using an adenosine A2A receptor agonist. J Orthop Res 22 (2004) 427-435
26. Cohen S.B., Leo B.M., Baer G.S., Turner M.A., Beck G., and Diduch D.R. An adenosine A2A receptor agonist reduces interleukin-8 expression and glycosaminoglycan loss following septic arthrosis. J Orthop Res 23 (2005) 1172-1178
27. Petrov R., MacDonald M.H., Tesch A.M., and Benton H.P. Inhibition of adenosine kinase attenuates interleukin-1- and lipopolysaccharide-induced alterations in articular cartilage metabolism. Osteoarthritis Cartilage 13 (2005) 250-257
28. Fini M., Giavaresi G., Carpi A., Nicolini A., Setti S., and Giardino R. Effects of pulsed electromagnetic fields on articular hyaline cartilage: review of experimental and clinical studies. Biomed Pharmacother 59 (2005) 388-394
29. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.-N., and Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53 (2001) 527-552
30. 2A adenosine receptors in chronic heart failure and cardiac transplantation. FASEB J 17 (2003) 280-282
31. 3 adenosine receptors in human neutrophils and promyelocitic HL60 cells: a pharmacological and biochemical study. Mol Pharmacol 61 (2002) 415-424
32. 3 adenosine receptors in human lymphocytes: upregulation in T cell activation. Mol Pharmacol 65 (2004) 711-719
33. Boyle D.L., Sajjadi F.G., and Firestein G.S. Inhibition of synoviocytes collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 39 (1996) 923-930
34. 2A receptor-mediated responses. J Immunol 175 (2005) 555-565
35. Boyle D.L., Moore J., Yang L., Sorkin L.S., and Firestein G.S. Spinal adenosine receptor activation inhibits inflammation and joint destruction in rat adjuvant induced arthritis. Arthritis Rheum 46 (2002) 3076-3082
36. Aaron R.K., Boyan B.D., Ciombor D.M., Schwartz Z., and Simon B.J. Stimulation of growth factor synthesis by electric and electromagnetic fields. Clin Orthop Relat Res 419 (2004) 30-37
37. De Mattei M., Caruso A., Traina G.C., Pezzetti F., Baroni T., and Sollazzo V. Correlation between pulsed electromagnetic fields exposure time and cell proliferation increase in human osteosarcoma cell lines and human normal osteoblast cells in vitro. Bioelectromagnetics 20 (1999) 177-182
38. Pezzetti F., De Mattei M., Caruso A., Cadossi R., Zucchini P., Carinci F., et al. Effects of pulsed electromagnetic fields on human chondrocytes: an in vitro study. Calcif Tissue Int 65 (1999) 396-401
39. De Mattei M., Pasello M., Pellati A., Stabellini G., Massari L., Gemmati D., et al. Effects of electromagnetic fields on proteoglycan metabolism of bovine articular cartilage explants. Connect Tissue Res 44 (2003) 154-159
40. De Mattei M., Pellati A., Pasello M., Ongaro A., Setti S., Massari L., et al. Effects of physical stimulation with electromagnetic field and insulin growth factor-I treatment on proteoglycan synthesis of bovine articular cartilage. Osteoarthritis Cartilage 12 (2004) 793-800
41. De Mattei M., Fini M., Setti S., Ongaro A., Gemmati D., Stabellini G., et al. Proteoglycan synthesis in bovine articular cartilage explants exposed to different low-frequency low energy pulsed electromagnetic fields. Osteoarthritis Cartilage 15 (2007) 163-168
42. Ciombor D.M., Aaron R.K., Wang S., and Simon B. Modification of osteoarthritis by pulsed electromagnetic field - a morphological study. Osteoarthritis Cartilage 11 (2003) 455-462
43. Fini M., Torricelli P., Giavaresi G., Aldini N.N., Cavani F., Setti S., et al. Effect of pulsed electromagnetic field stimulation on knee cartilage, subchondral and epyphiseal trabecular bone of aged Dunkin Hartley guinea pigs. Biomed Pharmacother (2007) [Epub ahead of print]
44. Trock D.H., Bollet A.J., and Markoll R. The effect of pulsed electromagnetic fields in the treatment of osteoarthritis of the knee and cervical spine. Report of randomized, double blind, placebo controlled trials. J Rheumatol 21 (1994) 1903-1911
45. Zorzi C., Dall'Oca C., Cadossi R., and Setti S. Effects of pulsed electromagnetic fields on patients' recovery after arthroscopic surgery: prospective, randomized and double-blind study. Knee Surg Sports Traumatol Arthrosc 15 (2007) 830-834
46. Varani K., De Mattei M., Vincenzi F., Gessi S., Merighi S., Pellati A., et al. Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields. Osteoarthritis Cartilage (2007) [Epub ahead of print]
47. 2A adenosine receptors in human neutrophils. Br J Pharmacol 136 (2002) 57-66
48. 3 adenosine receptors in human neutrophils and low frequency electromagnetic fields. Biochem Pharmacol 66 (2003) 1897-1906
49. Park H.J., Lee S.H., Son D.J., Oh K.W., Kim K.H., Song H.S., et al. Antiarthritic effect of bee venom: inhibition of inflammation mediator generation by suppression of NF-kappaB through interaction with the p50 subunit. Arthritis Rheum 50 11 (2004) 3504-3515
50. Stebulis J.A., Rossetti R.G., Atez F.J., and Zurier R.B. Fibroblast-like synovial cells derived from synovial fluid. J Rheumatol 32 (2005) 301-306
51. Upragarin N.A., Van Asten P.C., Topten W., Landman J.M., and Gruys E. Serum amyloid a production by chicken fibroblast-like synoviocytes. Vet Immunol Immunopathol 106 (2005) 39-51
52. Woclawek-Potocka I., Okuda K., Acosta T.J., Korzekwa A., Pilawski W., and Skarzynski D.J. Phytoestrogen metabolites are much more active than phytoestrogens themselves in increasing prostaglandin F(2alpha) synthesis via prostaglanin F(2alpha) synthase-like 2 stimulation in bovine endometrium. Prostaglandins Other Lipid Mediat 78 (2005) 202-217
53. 2A adenosine receptors. Life Sci 59 (1996) 1373-1388
54. 3H-CGS 21680 binding. Br J Pharmacol 117 (1996) 1693-1701
55. 3[H]-MRE 2029F20. Mol Pharmacol 67 (2005) 1-11
56. Varani K., Cacciari B., Baraldi P.G., Dionisotti S., Ongini E., and Borea P.A. Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors. Life Sci 63 (1998) 81-87
57. Seamon K.B., and Daly J.W. Forskolin: a unique diterpene activator of cyclic AMP-generating systems. J Cyclic Nucleotide Res 7 4 (1981) 201-224
58. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
59. Ahmed S., Pakozdi A., and Koch A.E. Regulation of interleukin-1beta-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 54 (2006) 2393-2401
60. Tomita T., Kunugiza Y., Tomita N., Takano H., Morishita R., Kaneda Y., et al. E2F decoy oligodeoxynucleotide ameliorates cartilage invasion by infiltrating synovium derived from rheumatoid arthritis. Int J Mol Med 18 2 (2006) 257-265
61. Kojima F., Naraba H., Sasaki Y., Beppu M., Aoki H., and Kawai S. Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum 48 (2003) 2819-2828
62. Schulte G., and Fredholm B.B. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 15 9 (2003) 813-827
63. Ciccarelli R., D'Alimonte I., Ballerini P., D'Auro M., Nargi E., Buccella S., et al. Molecular signalling mediating the protective effect of A1 adenosine and mGlu3 metabotropic glutamate receptor activation against apoptosis by oxygen/glucose deprivation in cultured astrocytes. Mol Pharmacol 71 5 (2007) 1369-1380 [Epub 2007 Feb 9]